• Sponsored by the National Institutes of Health - National Institute of Neurological Disorders and Stroke (NIH-NINDS), the study, known as CombiRx, will determine if the combined use of each treatment reduces relapse rate when compared to either agent alone. (news-medical.net)
  • We will discuss current concepts of relapse regulation by focusing on immune and molecular mechanisms of neuroinflammation, oligodendrocyte damage, myelin loss and axonal degeneration. (eurekaselect.com)
  • There is an insufficient remyelination in the lesions of multiple sclerosis (MS). One of the factor that was found to promote remyelination is neuregulin-1 which is the ligand of ErbB4. (hindawi.com)
  • Restricting the research only to relapses, it seems that alemtuzumab is the most cost effective When a company considers that there is enough information from clinical trial to fill an application, they submit to the regulatory agencies a request for approval. (wikipedia.org)
  • Finally, perspectives in further optimization and development of more suitable experimental models to study human relapsingremitting MS will be discussed. (eurekaselect.com)